Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients

Kidney International

Volumn 57, Issue 2, 2000, Pages 590-600

  Chan, Juliana C N ^a   Ko, Gary T C ^a   Leung, Denis H Y ^a   Cheung, Robert C K ^a   Cheung, Margaret Y F ^a   So, Wing Yee ^a   Swaminathan, Ramasmyiyer ^a   Nicholls, M Gary ^a   Critchley, Julian A J H ^a   Cockram, Clive S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Albuminuria; Blood pressure; Cardiovascular disease; Enalapril; Nifedipine; Renal hemodynamics

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; NIFEDIPINE;

ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MICROALBUMINURIA; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME;

EID: 0033945051     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00879.x     Document Type: Article

References (56)

1. 1. STAMLER J, VACCARO O, NEATON JD, WENTWORTH D: Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444, 1993
2. 2. PARVING HH, ANDERSEN AR, SMIDT UM, HOMMEL E, MATHIESEN ER, SVENDSEN PA: Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J 294:1443-1447, 1987
3. 3. FULLER JH, STEVENS LK, WANG SL: International variations in cardiovascular mortality associated with diabetes mellitus: The WHO Multinational Study of Vascular Disease in Diabetes. Ann Med 28:319-322, 1996
4. 4. PYÖRÄLÄ K, PEDERSEN TR, KJEKSHUS J, FAERGEMAN O, OLSSON AG, THORGEIRSSON G, THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S) GROUP: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A sub-group analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620, 1997
5. 5. KUUSISIO J, MYKKANEN L, PYORALA K: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43:960-967, 1994
6. 6. THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
7. 7. OHKUBO Y, KISHIKAWA H, ARAKI E, MIYATA T, ISAMI S, MOTOYOSHI S, KOJIMA Y, FURUYOSHI N, SHICHIRI M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: A randomised prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
8. 8. HOSTETTER TH: Mechanisms of diabetic nephropathy. Am J Kidney Dis 23:188-192, 1994
9. 9. KASISKE BL, KALIL RS, MA JZ, LIAO M, KEANE WF: Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 118:129-138, 1993
10. 10. LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
11. 11. RAVID M, LANG R, BACHMANI R, LISHNER M: Long term renoprotective effect of angiotensin converting enzyme inhibition in non-insulin dependent diabetes mellitus: A 7 year follow up study. Arch Intern Med 156:286-289, 1996
12. 12. AHMAD J, SIDDIQUI MA, AHMAD H: Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 20:1576-1581, 1997
13. 13. VELUSSI M, BROCCO E, FRIGATO F, ZOLLI M, MUOLLO B, MAIOLI M, CARRARO A, TONOLO G, FRESU P, CERNIGOI AM, FIORETTO P, NOSADINI R: Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 45:216-222, 1996
14. 14. CHAN JCN, COCKRAM CS, NICHOLLS MG, CHEUNG CK, SWAMINATHAN R: Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: One year analysis. Br Med J 305:981-985, 1992
15. 15. MELBOURNE DIABETIC NEPHROPATHY STUDY GROUP: Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Br Med J 302:210-216, 1991
16. 16. UKPDS: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 8). Br Med J 317:703-713, 1998
17. 17. UKPDS: Efficacy of atenolol and caplopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). Br Med J 317:713-720, 1998
18. 18. TATTI P, PAHOR M, BYINGTON R, MAURO PD, GUARISCO R, STROLOL G, STROLLO F: Outcome results of the fosinopril versus amlodipine cardiovascular events randomised trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21:597-603, 1998
19. 19. RAYMOND OE, JEFFERS BW, HIATI WR, BIGGERSTAFF SL, GIFFORD N, SCHRIER RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with NIDDM and hypertension. N Engl J Med 338:645-652, 1998
20. 20. WORLD HEALTH ORGANISATION: Diabetes mellitus: Report of a WHO Study group (Technical reports series 727). Geneva, World Health Organisation, 1985, p 11
21. 21. FRIEDEWALD WT, LEVY RI, FREDRICKSON DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
22. 22. CHEUNG CK, SWAMINATHAN R: Rapid, economical immunoturbidimetric method for albuminuria. Clin Chem 33:204-205, 1987
23. 23. MOGENSEN CE, VESTBO E, POULSEN PL, CHRISTIANSEN C, DAMS-GAARD EM, EISKJÆR H, FRØLAND A, HANSEN KW, NIELSEN S, PEDERSEN MM: Microalbuminuria and potential confounders. Diabetes Care 18:572-581, 1995
24. 24. The World Health Report 1997: Conquering suffering, enriching humanity. Geneva, World Health Organisation, 1997
25. 25. ALLAWI J, RAO PV, GILBERT R, SCOTT G, JARRETT RJ, KEEN H, VIBERTI GC, MATHER HM: Microalbuminuria in non-insulin-dependent diabetes: Its prevalence in Indian compared with Europoid patients. Br Med J 296:462-464, 1988
26. 26. YOUNG RP, CHAN JCN, POON E, CRITCHLEY JAJH, COCKRAM CS: Associations between albuminuria and angiotensinogen T235 and angiotensin converting enzyme deletion polymorphims in Chinese NIDDM patients. Diabetes Care 21:431-437, 1997
27. 27. RITZ E, NOWACK R, FLISER D, KOCH M, TSCHOPE W: Type II diabetes mellitus: Is the renal risk adequately appreciated. Nephrol Dial Transplant 6:679-682, 1991
28. 28. COWIE CC, PORT FK, WOLFE RA: Disparities in incidence of diabetes end stage renal disease according to race and type of diabetes. N Engl Med 321:1074-1079, 1989
29. 29. DEFRONZO RA, FERRANNINI E: Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991
30. 30. PARVING H-H: Renal protection in diabetes: An emerging role for calcium antagonists. J Hypertens 14(Suppl 4):S21-S25, 1996
31. 31. RAVID M, BROSH D, RAVID-SAFRAN D, LEVY, RACHMANI R: Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure and hyperglycaemia. Arch Intern Medicine 158:998-1004, 1998
32. 32. MASCHIO G, ALBERTI D, JANIN G, LOCATELLI F, MANN J, MOROLESE M, PONTICELLI C, RIIZ E, ZUCCHELLI P: Effect of the angiotensin converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939-945, 1996
33. 33. THE GISEN GROUP: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in porteinuric, non-diabetic nephropathy. Lancet 349:1857-1863, 1997
34. 34. HANNEDOUCHE T, LANDAIS P, GOLDFARB B, ESPER NE, FOURNIER A, GODIN M, DURAND D, CHANARD J, MlGNON F, SUC J-M, GRUNFEID J-P: Randomised controlled trial of enalapril and beta blockers in non diabetic chronic renal failure. Br Med J 309:833-837, 1994
35. 35. THE HYPERTENSION AND DIABETES STUDY GROUP: Hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 11:309-317, 1993
36. 36. CHAN JCN, CHEUNG CK, SWAMINATHAN R, NICHOLLS MG, COCKRAM CS: Obesity, albuminuria and hypertension among Hong Kong Chinese with non-insulin-dependent diabetes mellitus (NIDDM). Postgrad Med J 69:204-210, 1993
37. 37. DINNEEN SF, GERSTEIN HC: The association of microalbuminuria and mortality in NIDDM. Arch Intern Med 257:1413-1418, 1997
38. 38. BIOLLAZ J, BRUNNER HR, GAVRAS I, WAEBER B, GAVRAS H: Antihypertensive therapy with MK-421: Angiotensin II renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 4:966-972, 1982
39. 39. MENTO PF, WILKES BM: Plasma angiotensins and blood pressure during converting enzyme inhibition. Hypertension 9(6 Pt 2; Suppl III): III42-III48, 1987
40. 40. URATA H, KINOSHITA A, MISONO KS, BUMPUS FM, HUSAIN A: Identification of a highly specific chymase as the major angiotensin II forming enzyme in the human heart. J Biol Chem 265:22348-22357, 1990
41. 41. ROSSING P, HOMMEL E, SMIDI UM, PARVING HH: Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int 45(Suppl):145-149, 1994
42. 42. CHAN JCN, NICHOLLS MG, CHEUNG CK, LAW LK, SWAMINATHAN R, COCKRAM CS: Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM. Diabetes Care 18:1001-1006, 1995
43. 43. SAWICKI PT, KAISER S, HEINEMANN L, FRENZEL H, BERGER M: Prevalence of renal artery stenosis in diabetes mellitus: An autopsy study. J Intern Med 229:489-492, 1991
44. 44. SELBY JV, FITZSIMMONS SC, NEWMAN JM, KATZ PP, SEPE S, SHOWSTACK J: The natural history of epidemiology of diabetic nephropathy: Implication for prevention and control. JAMA 263:1945-1960, 1990
45. 45. VALVO E, BEDOGNA V, CASAGRANDE P, ANTIGA L, ZAMBONI M, BOMMARTINI F, OLDRIZZI L, RUGIU C, MASCHIO G: Captopril in patients with type II diabetes and renal insufficiency: Systemic and renal hemodynamic alterations. Am J Med 85:344-348, 1988
46. 46. PARVING H-H, TARNOW L, ROSSING P: The angiotensin-converting enzyme gene and its inhibition in diabetic nephropathy. Curr Opin Endocrinol Diabetes 3:315-321, 1996
47. 47. RAVID M, NEUMANN L, LISHNER N: Plasma lipids and the progression of nephropathy in diabetes mellitus type II: Effect of ACE inhibitors. Am J Kidney Dis 47:907-910, 1995
48. 48. LAM KS, CHEW IKP, JANUS ED, PANG RWC: Cholesterol lowering therapy is may retard the progression of diabetic nephropathy. Diabetologia 38:604-609, 1995
49. 49. KASISKE BL, CLEARY MP, O'DONNELL MP, KEANE WF: Effects of genetic obesity on renal structure and function in Zucker rat. J Lab Clin Invest 106:598-604, 1985
50. 50. KASISKE BL, O'DONNELL MP, CLEARY MP, KEANE WF: Treatment or hyperlipidaemia reduces glomerular injury in obese Zucker rats. Kidney Int 33:667-672, 1988
51. 51. KEILANI T, SCHLUETER W, LEVIN ML, BATLLE DC: Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin converting enzyme inhibitor. Ann Intern Med 18:246-254, 1993
52. 52. CHAN JCN, YEUNG VTF, LEUNG DHY, TOMIINSON B, NICHOLLS MG, COCKRAM CS: The effects of enalapril and nifedipine on carbohydrate and lipid metabolism in NIDDM. Diabetes Care 17:859-862, 1994
53. 53. UKPDS: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
54. 54. CHAN JCN, CHEUNG CK, CHEUNG MYF, SWAMINATHAN R, CRITCHLEY JAJH, COCKRAM CS: Abnormal albuminuria as a predictor of mortality and renal impairment in Chinese patients with NIDDM. Diabetes Care 18:1013-1014, 1995
55. 55. ROSSETTI L, GIACCARI A, DEFRONZO RA: Glucose toxicity. Diabetes Care 13:610-630, 1990
56. 56. KOYA D, KING GL: Protein kinase C activation and the development of diabetic complications. Diabetes 47:859-866, 1998